乙肝清热解毒胶囊联合拉米夫定治疗活动性肝炎肝硬化疗效分析  

Analysis on effect of hepatitis B Qingrejiedu capsule and lamivudine in treatment of patients with active liver cirrhosis

作　　者：徐菁[1] 葛风芹[1] 黄桂芹[1] 李沧友 耿建洪 

机构地区：[1]沧州市传染病医院感染二科,河北沧州061001

出　　处：《中国肝脏病杂志（电子版）》2009年第1期16-18,共3页Chinese Journal of Liver Diseases：Electronic Version

摘　　要：目的观察乙肝清热解毒胶囊联合拉米夫定对活动性肝炎肝硬化患者的疗效。方法选择168例中医辨证为肝胆湿热型的活动性肝炎肝硬化患者,按1∶1比例随机分为两组,治疗组口服乙肝清热解毒胶囊及拉米夫定,对照组单用拉米夫定,疗程18个月。结果治疗组治疗后在肝功复常率、HBVDNA低于检测下限的比率、HBeAg低于检测下限的比率、YMDD变异率方面均优于对照组且差异具有显著性,P<0.05。结论乙肝清热解毒胶囊联合拉米夫定对活动性肝炎肝硬化疗效显著,且在抑制YMDD变异方面有一定疗效。Objective To observe the treatment effect of patients with active liver cirrhosis by the joint effort of hepatitis B Qingrejiedu capsule and lamivudine. Methods One hundred and sixty eight patients with active hepatitis liver cirrhosis belonged to liver and gallbladder damp heat type which is diagnosed by Chinese traditional medicine were selected, they were randomly divided into two groups according to the ratio of 1:1. The patients in the treatment group take oral hepatitis B Qingrejiedu capsules and lamivudine, while patients in the control group only take lamivudine, both treated for 18 months. Results After the treatment, normalization rate in liver function, HBV DNA negative conversion rate, HBeAg negative conversion rate and YMDD mutation rate were compared between the two groups, which were all superior in the treatment group than that in the control group, and the differences were significant, P < 0.05. Conclusions The joint effort of hepatitis B Qingrejiedu capsule and lamivudine on the treatment of active hepatitis cirrhosis has a significant effect, which also plays certain role in the inhibition of YMDD variation.

关 键 词：活动性肝炎肝硬化 乙肝清热解毒胶囊 拉米夫定 变异 

分 类 号：R575.2[医药卫生—消化系统]